Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma

The mechanisms behind acquired resistance to the proteasome inhibitor bortezomib in multiple myeloma remain to be elucidated. Here, the authors show that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, promotes its phase separation and alters H3K36me2 at certain gene promoters re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jing Liu, Ying Xie, Jing Guo, Xin Li, Jingjing Wang, Hongmei Jiang, Ziyi Peng, Jingya Wang, Sheng Wang, Qian Li, Linquan Ye, Yuping Zhong, Qiguo Zhang, Xiaozhi Liu, David M. Lonard, Jin Wang, Bert W. O’Malley, Zhiqiang Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/695b13f642e84ed19489e07ffe4eec6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:695b13f642e84ed19489e07ffe4eec6b
record_format	dspace
spelling	oai:doaj.org-article:695b13f642e84ed19489e07ffe4eec6b2021-12-02T14:03:50ZTargeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma10.1038/s41467-021-21386-y2041-1723https://doaj.org/article/695b13f642e84ed19489e07ffe4eec6b2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21386-yhttps://doaj.org/toc/2041-1723The mechanisms behind acquired resistance to the proteasome inhibitor bortezomib in multiple myeloma remain to be elucidated. Here, the authors show that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, promotes its phase separation and alters H3K36me2 at certain gene promoters resulting in a transcriptional profile that favors resistance of myeloma cells to bortezomib.Jing LiuYing XieJing GuoXin LiJingjing WangHongmei JiangZiyi PengJingya WangSheng WangQian LiLinquan YeYuping ZhongQiguo ZhangXiaozhi LiuDavid M. LonardJin WangBert W. O’MalleyZhiqiang LiuNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Jing Liu Ying Xie Jing Guo Xin Li Jingjing Wang Hongmei Jiang Ziyi Peng Jingya Wang Sheng Wang Qian Li Linquan Ye Yuping Zhong Qiguo Zhang Xiaozhi Liu David M. Lonard Jin Wang Bert W. O’Malley Zhiqiang Liu Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
description	The mechanisms behind acquired resistance to the proteasome inhibitor bortezomib in multiple myeloma remain to be elucidated. Here, the authors show that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, promotes its phase separation and alters H3K36me2 at certain gene promoters resulting in a transcriptional profile that favors resistance of myeloma cells to bortezomib.
format	article
author	Jing Liu Ying Xie Jing Guo Xin Li Jingjing Wang Hongmei Jiang Ziyi Peng Jingya Wang Sheng Wang Qian Li Linquan Ye Yuping Zhong Qiguo Zhang Xiaozhi Liu David M. Lonard Jin Wang Bert W. O’Malley Zhiqiang Liu
author_facet	Jing Liu Ying Xie Jing Guo Xin Li Jingjing Wang Hongmei Jiang Ziyi Peng Jingya Wang Sheng Wang Qian Li Linquan Ye Yuping Zhong Qiguo Zhang Xiaozhi Liu David M. Lonard Jin Wang Bert W. O’Malley Zhiqiang Liu
author_sort	Jing Liu
title	Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
title_short	Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
title_full	Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
title_fullStr	Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
title_full_unstemmed	Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
title_sort	targeting nsd2-mediated src-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/695b13f642e84ed19489e07ffe4eec6b
work_keys_str_mv	AT jingliu targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT yingxie targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT jingguo targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT xinli targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT jingjingwang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT hongmeijiang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT ziyipeng targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT jingyawang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT shengwang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT qianli targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT linquanye targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT yupingzhong targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT qiguozhang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT xiaozhiliu targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT davidmlonard targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT jinwang targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT bertwomalley targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma AT zhiqiangliu targetingnsd2mediatedsrc3liquidliquidphaseseparationsensitizesbortezomibtreatmentinmultiplemyeloma
_version_	1718392084890648576

Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma

Ejemplares similares